Advanced Discovery Research is looking for people with schizophrenia to participate in research studies. If you qualify, you may be compensated up to $3,800.00 for your participation depending on the study.

About The Studies: 

Advanced Discovery Research has studies for individuals with schizophrenia that are looking at the use of medication or a digital phone app to help with schizophrenia symptoms.  

Cereval Empower Study:

This study is an open-label study that would provide the study drug and regular clinic visits for up to 1 year. An open-label study means that participants will receive the active study drug without the possibility of getting a placebo, or inactive drug.  This study is looking at how the drug work during long-term treatment.

The study drug, called emraclidine, is thought to work differently from current antipsychotics.  Instead of blocking dopamine receptors, emraclidine targets a different system entirely called the muscarinic system. Emraclidine is a M4 positive allosteric modulator, meaning that it helps enhance the activity at a specific receptor, called the M4 muscarinic acetylcholine receptor.  Activity at this receptor is thought to reduce excess levels of the neurotransmitter dopamine and may potentially reduce symptoms of schizophrenia without causing many of the side effects seen with therapies that directly block dopamine receptors.

The Click CONVOKE study:

This study is researching 2 different mobile apps to see if they are safe and effective in helping people who have certain symptoms of schizophrenia. If you choose to participate, you will use a mobile application on your personal smartphone. Participants will be randomly assigned (like the flip of a coin) to use one app or the other. This study lasts up to 22 weeks. If you complete the study, you will have the chance to participate in an extension study for another 20 weeks.

Frequently Asked Questions

Will participants benefit from this study?
It is possible study participants could receive some benefit, but that is not guaranteed. However, information gathered in this study may help people in the future with schizophrenia symptoms.

What are the risks related to this study?
It is possible participants could experience one or more side effects during this study. The study staff will talk with all participants about any potential study-related risks and side effects.

Because research studies can affect participants’ health, all participants will be closely monitored. Researchers for this study designed a protocol, which explains the study in detail.

An independent review board responsible for participant safety has reviewed this protocol. The board also requires that the protocol be followed exactly as written.

Is study participation required?
No, participation in this study is not required.

Potential participants can talk with the study doctor about the study and other treatment options before deciding to enroll in this study. The study doctor will also discuss the risks and benefits related to other treatment options.

Additionally, enrolled study participants may stop their participation at any time and for any reason.

Who is eligible to participate in this study?
You may be able to participate if you:

• Are at least 18 years of age
• Have a primary diagnosis of schizophrenia
• Have been on a stable dose of antipsychotic medication for at least 12 weeks before the study treatment period
• Meet additional study criteria

About Research Studies

Research studies are different than regular medical care because the purpose of research studies is to gather information about an investigational drug.

Pharmaceutical companies use research studies to evaluate an investigational drug’s safety and effectiveness.

Using the information collected in research studies, doctors and regulatory agencies can determine if an investigational drug for a specific condition could one day be made available to the public.